Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01538966 · ClinicalTrials.gov registry record · NA
Acromegaly Combination Treatment Study
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT01538966 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 76 participants.
The verdict
NCT01538966, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a lower cost, compared to combination high dose SRL and weekly pegvisomant. Lower doses of therapy will greatly reduce cost of acromegaly therapy.
Interventions
- DRUG Lanreotide
- DRUG Pegvisomant
- DRUG Octreotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-03-29 |
| Est. Completion | 2022-05-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01538966
The ClinicalTrials.gov registry entry for NCT01538966 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lanreotide is the first listed.
NCT01538966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01538966 about?
NCT01538966 is a clinical study titled "Acromegaly Combination Treatment Study". In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a lower cost, compared to combination high dose SRL and weekly pegvisoman...
What is the current status of trial NCT01538966?
This trial is currently terminated. It is a NA study. The enrollment target is 76 participants. The study started on 2012-03-29. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT01538966?
The interventions under investigation include: Lanreotide (DRUG), Pegvisomant (DRUG), Octreotide LAR (DRUG).
Who is sponsoring clinical trial NCT01538966?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.